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Neomycin, an antibiotic previously thought o interact specifically with inositol-containing phospholipids, 
was found to inhibit IP,-mediated Ca2+ release from the intracellular stores of permeabilized insulinoma 
and liver cells. This inhibition could be relieved by increasing the IP, concentration. Radiolabelled IP, was 
found to bind tightly to columns prepared from neomycin covalently attached to glass beads. ATP was also 
bound by these colums. It is concluded that neomycin acts in biological systems as a weak anion exchanger 
and is therefore unsuitable for use as a specific tool to study the role of inositol phospholipids in intracellular 
signalling. 
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1. INTRODUCTION 
The prolonged therapeutic use of neomycin, a 
cationic aminoglycoside antibiotic, results in an 
impairment of hearing and damage to the kidneys. 
In studying the biochemical basis for this toxicity, 
Schacht and co-workers [ 1,2] noted that neomycin 
could bind tightly and selectively to polyphospho- 
inositides. It was also shown that neomycin in- 
terfered with the enzymatic synthesis and 
breakdown of these lipids [3-61. 
It is now recognized that the inositol-containing 
phospholipids in the plasmalemma serve as precur- 
sors for at least two important intracellular 
messengers. These are 1,2-diacylglycerol and D- 
myo-inositol 1,4,5trisphosphate (IP3) whose func- 
tions respectively are to stimulate protein kinase C 
and to induce Ca’+ release from intracellular stores 
(review [7]). These compounds are formed as 
products of the phospholipase C catalyzed hy- 
drolysis of phosphatidylinositol 4$bisphosphate 
(PIPz). The known interaction of neomycin with 
PIP2 [ 1,2] has provided the basis for the use of this 
antibiotic as a tool to study the possible involve- 
ment of PIP2 hydrolysis in biological processes. 
For example, neomycin was found to suppress 
Ca2+ transients evoked by electrical excitation of 
skeletal muscle [a]. This observation is consistent 
with the proposal that IP3 also has a messenger 
role in skeletal muscle and that neomycin acts to 
inhibit the generation of IP3 by inhibiting phos- 
pholipase C-mediated PIP2 breakdown [3-6,8]. 
The experiment, however, does not exclude the 
possibility that neomycin has some direct in- 
hibitory effect on Ca’+ release from the sar- 
coplasmic reticulum [a]. Here we show that 
neomycin indeed exerts an inhibitory effect on 
IP3-mediated Ca2+ release from permeabilized 
cells. However, this inhibition could be entirely ac- 
counted for by the ability of neomycin to bind IP3. 
This aspect of the action of neomycin is discussed 
in relation to the utility of using this antibiotic to 
study signal transduction involving the inositol 
lipids. 
2. MATERIALS AND METHODS 
RINmSF insulinoma cells and rat hepatocytes 
were isolated as described [9,10]. The preparation 
of Ca2+ electrodes and their calibration were per- 
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formed as in (111. When IP3-mediated 45Ca2+ 
release was measured the hepatocytes (10 mg dry 
wt/ml) were permeabilized and preloaded with 
45~2+ in a medium containing 120 mM KCl, 
20 mM Tris-Hepes (pH 7.2), 0.3 mM MgC12, 
1.0 mM MgATP, 20 mM phosphocreatine, 
10 U/ml creatine kinase, 200 pg/ml saponin, 2 FM 
ruthenium red, 5 PM antimycin A, 0.5 mM EGTA 
and 2 &i/ml 45CaZ+. Sufficient CaCl2 was added 
to this medium to give a free [Ca2”] of 140 nM as 
determined with the Cazf electrode. After 25 min 
incubation at 3O”C, a 0.1 ml aliquot of cells was 
diluted 50-fold into a medium containing 120 mM 
KC1 and 20 mM Tris-Hepes (pH 7.2). 5 s after the 
dilution, the 45Ca2+ remaining in the cells was 
measured after separation of the cells from the 
medium using Whatman glass-fiber filters (GF/C, 
0.24 mm). The filters were washed twice with 
5.0 ml of 0.25 M sucrose and counted in 15 ml of 
scintillation fluid (ACS II, Amersham Co.). 
IP3-mediated 45Ca2+ release was calculated from 
the difference between the counts retained on the 
filter in the presence and absence of IP3 and the 
known specific activity of the isotope. 
Neomycin B sulfate (Sigma) was reductively 
coupled to glass beads (CPG/CDI-Glycophase; 
particle size 74-125 pm; Pierce, Rockford, IL) as 
described by Schacht [l]. [2-3H]IP3, L-myo- 
[U-14C]inositol l-phosphate, [32P]ATP and 45Ca2t 
were from Amersham. New England Nuclear sup- 
plied the [3H]PIP~. The IP, used in these studies 
was a generous gift from Dr Robin Irvine and was 
also obtained from Sigma. 
3. RESULTS 
To examine possible effects of neomycin on the 
release of Ca2+ induced by IP3, the action of the 
antibiotic was tested in saponin permeabilized 
RINmSF insulinoma cells incubated in the 
presence of mitochondrial inhibitors. Fig. 1 shows 
that neomycin inhibits IP3-mediated Ca2+ release 
in a dose-dependent manner. At a low concentra- 
tion of neomycin (0.25 mM; fig.lB) only the ef- 
fects of submaximal concentrations of IP3 were in- 
hibited. When higher concentrations of neomycin 
were used (1.25 mM; fig.lC) the response to max- 
imal concentrations of I& was also attenuated. 
Fig. 1 further shows that neomycin also inhibits the 
initial rate of net Ca2+ uptake. This is reflected by 
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Fig. i. The effect of various concentrations of neomycin 
on the dose response of IPs-mediated Cat* release. lo6 
RINmSF cells were incubated at 30°C and pH 7.0 in 
0.2 ml of a buffer containing 110 mM KCl, 10 mM 
NaCl, 2 mM KHzPO~, 1 mM MgClz, 25 mM Hepes, 
1 mM MgATP, 5 mM phosphocreatine, 20 units of 
creatine kinase/ml, 1 pg/ml oligomycin and 0.2 pM 
antimycin A. Saponin (50pg/ml) was added to 
permeabilize the cells and the change in medium free 
Ca2+ was measured with a Ca2+ electrode. At the points 
indicated by the arrows pulse additions of IP3 were 
made. From left to right these concentrations were (in 
pM): 0.125, 0.25, 0.5, 1.0, 2.5. (A) Control, (B) 
neomycin (0.25 mM), (C) neomycin (1.25 mM). 
Neomycin was added 6 min after cell permeabilization 
with saponin when the non-mitochondrial pool had 
lowered the medium free [Ca2’] to pCa2’ = 5.9. 
a progressive inhibition of the amount of Ca2+ ac- 
cumulated into the non-mitochondrial pool during 
the 4 min preceding the first pulse addition of IPJ 
(fig. 1). 
Experiments of the type shown in fig.1 do not 
allow the effects of neomycin on Ca2+ uptake to be 
easily distinguished from its effects on 
IP3-mediated Ca2+ release. For this reason an 
alternative experimental protocol was employed in 
which cells were pre-loaded with 4sCa2+ and then 
diluted into medium containing IP3 in the presence 
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Fig.2. The influence of neomycin on IPs-mediated 
45CaZ+ release from permeabilized hepatocytes. The 
release of 4sCa2+ from pre-loaded hepatocytes was 
measured exactly as described in section 2. The results 
shown are the mean f SE of 3 separate experiments. 
or absence of neomycin. The results of these ex- 
periments, performed with rat hepatocytes, are 
shown in fig.2. The data obtained measuring 
45Ca2+ release from hepatocytes were in qualitative 
agreement with the Ca2+ electrode studies using in- 
sulinoma cells. Thus, neomycin (1.25 mM) 
markedly inhibited the effects of low concentra- 
tions of IPj but the magnitude of the inhibition 
diminished as the IP3 concentration was increased. 
One hypothesis that is consistent with the data in 
figs 1 and 2 is that neomycin (a polycationic 
molecule) may inhibit IP3-mediated Ca2+ release 
simply by chelating added anionic IP3. To test this 
hypothesis, columns were prepared containing 
neomycin covalently linked to glass beads [I]. 
More than 90% of the labelled IP3 added was 
found to be retained by such a column (table 1). L- 
myo-Inositol l-phosphate (IPi) and myo-inositol 
were bound to a much lower extent whereas ATP 
was avidly bound. Greater than 85% of the bound 
IP3 or ATP could be eluted from the column with 
12 ml of 0.4 M ammonium formate/O.l M formic 
acid (not shown). As shown previously [l], PIP2 
was also retained by the column (table 1). Signifi- 
cant non-specific binding of IP3 can be excluded by 
the finding that only 11% of the IP3 was retained 
by columns prepared from glass beads carried 
through the preparative procedure without the ad- 
dition of neomycin (table 1). 
4. DISCUSSION 
Neomycin, a polycationic antibiotic, is generally 
thought to bind specifically to polyphosphoinosi- 
tides and has therefore been widely used to study 
the involvement of this class of lipids in a variety 
of cellular processes. For example, it has been 
Table 1 
The ability of several phosphorylated compounds to bind to neomycin 
Counts loaded 
on column 
(cpm) 
Counts eluting 
in void volume 
(cpm) 
% bound 
[3HlIP3 (1PM) 1372 96 93 
t4ClIP, (1 PM) 10050 8760 13 
myo-[3H]Inositol (1 PM) 63 156 51080 19 
[3H]PIP2 (1 pg/ml) 994 301 70 
[32P]ATP (1 PM) 3672 123 97 
[32P]ATP (1 mM) 13359 199 98 
[3H]IP3, no neomycin 1372 1219 11 
Water soluble radiolabelled compounds were dissolved in 0.8 ml of 120 mM KC1 and 20 mM Tris-Hepes 
(pH 7.2) (buffer A) containing 1 pM of the corresponding unlabelled compound. Samples were loaded 
onto a 0.5 ml column of neomycin-coated glass beads previously equilibrated with buffer A. The void 
volume was collected along with an additional 0.8 ml column wash with buffer A. (3H]PIPz and 1 pg PIP2 
were loaded on the column dissolved in 2.0 ml CHCl3:MeOH (2: 1, v/v), and the void volume was 
collected as described above 
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shown to block excitation-contraction coupling in 
skeletal muscle [8], Ca2+-dependent histamine 
secretion from GTP-y-S loaded mast cells [ 121, 
thrombin-stimulated initiation of cell proliferation 
[ 131 and amylase secretion in response to carbachol 
from permeabilized pancreatic acini [ 141. These in- 
hibitory effects of neomycin have been used as 
strong evidence to link polyphosphoinositide 
breakdown to these different biological events. 
The results of this study demonstrate additional ef- 
fects of neomycin that are distinguished from its 
action on phospholipids. Using two different cell 
types (insulinoma and hepatocytes), we observed 
that neomycin markedly inhibits IPs-induced Ca2+ 
release from non-mitochondrial pools. In addi- 
tion, MgATP-dependent uptake into these pools 
was also inhibited. Both these effects can be ac- 
counted for by the ability of neomycin to bind IP3 
and ATP even more avidly than phosphatidylino- 
sitol 4,5bisphosphate. Since neomycin barely 
binds IPr, it appears that the antibiotic behaves as 
a weak anion exchanger. 
These observations raise questions regarding the 
specificity of this drug. It should be stressed that 
our data do not necessarily invalidate the conclu- 
sions drawn from previous studies where neomycin 
has been used as a probe to assess the involvement 
of inositol lipids. However, it should be recognized 
that neomycin has the potential to interact with 
polyphosphoinositides, IP3, a variety of nucleotide 
triphosphates including ATP and possibly other 
polyanions. Thus, the usefulness of neomycin as a 
specific drug to study polyphosphoinositide 
metabolism is questionable. The above results also 
cast doubts that the nephro- and ototoxicity of the 
aminoglycosides can be simply explained by an in- 
teraction with the polyphosphoinositides. 
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